UCSD Cancer Center Training Program in Drug Development

7.项目摘要/摘要 本次续签申请寻求资金，以继续开展非常成功的癌症治疗培训(CT2) 加州大学圣地亚哥分校摩尔综合癌症中心的项目。这项使命 CT2计划的目的是培养博士和内科科学家，他们将成为下一代领导者 在癌症治疗和诊断领域，成功翻译所需的每一个主要步骤 将以实验室为基础的发现转化为安全有效的治疗剂和诊断方式。第二号货柜码头 培训旨在定位受训者在肿瘤治疗领域发挥关键领导作用。这个 CT2项目的27名教员都是癌症中心的成员，他们的总部设在 医学院、斯克里普斯海洋研究所或普通校园。每位教职员工导师都是 成就卓著的研究员和教育家，有培养一流博士后研究员的历史。每个人都有 大量经同行评审的癌症或癌症相关研究资金。所有参与的教职员工都是 他们从事转化性研究，因为他们对新的癌症疗法感兴趣而被选中。 该方案被广泛纳入癌症中心的其他癌症相关活动和 加州大学圣迭戈分校。目标是在这个为期两年的项目中招聘和留住8名医学博士和博士科学家，该项目将 用于开发新的抗癌药物或指导使用这些药物所需的诊断学 个性化用药时代的药品。培训计划有3个组成部分：1)完成 正式的教学课程，涵盖药物开发过程中必不可少的工具；2)开展 在教师导师的指导下的药物或诊断开发研究项目；以及，3)必需 参加美国癌症研究协会或同等国家的年度会议 药物开发会议。受训人员还将参加癌症中心和科室 研讨会、研究回合和期刊俱乐部，以扩大他们对癌症研究的理解广度， 并编制正式的项目计划和做法或实际赠款申请，供执行委员会审查。 有方法确保所有受训人员接受负责任的行为原则的适当指导 研究和科学诚信。学员在全国范围内招募，并特别努力招募和 保留特殊的少数群体、妇女和弱势候选人。在其头10年的运营中， CT2项目吸引了来自全国主要研究型大学以及 生物医学科学与外科、血液学/肿瘤学和儿科临床培训课程。 这项计划非常成功，以至于癌症中心建立了一个平行的计划，由 由捐款资助的癌症治疗研究奖学金。

7. PROJECT SUMMARY/ABSTRACT This renewal application seeks funding to continue the highly successful Cancer Therapeutics Training (CT2) Program at the Moores Comprehensive Cancer Center at the University of California, San Diego. The mission of the CT2 program is to train the PhD and physician-scientists who will become the next generation of leaders in the field of cancer therapeutics and diagnostics in each of the major steps required for successful translation of laboratory-based discoveries into safe and effective therapeutic agents and diagnostic modalities. The CT2 training is designed to position trainees to play key leadership roles in the field of oncology therapeutics. The 27 faculty of the CT2 Program are all Members of the Cancer Center and are based in 10 departments in the School of Medicine, the Scripps Institute of Oceanography or the general campus. Each faculty mentor is an accomplished investigator and educator with a history of training superb post-doctoral fellows. Each has substantial peer-reviewed cancer or cancer-related research funding. All of the participating faculty are conducting translational research and have been selected because of their interest in new cancer therapeutics. This program is extensively integrated into the other cancer related activities of the Cancer Center and of UCSD. The goal is to recruit and retain 8 MD and PhD scientists in this two-year program that will position them for careers in the development of new cancer drugs or the diagnostics needed to guide the use of these drugs in the era of personalized medicine. The training program has 3 components: 1) the completion of formal didactic teaching sessions that cover tools essential to the drug development process; 2) the conduct of a drug or diagnostic development research project under the direction of a faculty mentor; and, 3) required participation in the annual meeting of the American Association for Cancer Research or an equivalent national drug development meeting. Trainees are also expected to participate in Cancer Center and Departmental seminars, research rounds and journal clubs to expand the breadth of their understanding of cancer research, and prepare formal project plans and practice or real grant applications for review by the Executive Committee. Methods are in place to ensure that all trainees are properly instructed in the principles of responsible conduct of research and scientific integrity. Trainees are recruited nationwide and special efforts are made recruit and retain exceptional minority, women and disadvantaged candidates. During its first 10 years of operation the CT2 Program has drawn trainees from major research universities across the country as well as from the Gradate Biomedical Sciences and Surgery, Hematology/Oncology, and Pediatric clinical training programs. This Program has been so successful that the Cancer Center has established a parallel program of additional fellowships in cancer therapeutics funded by donations.